Welcome to our dedicated page for Amesite SEC filings (Ticker: AMST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amesite Inc. filings document an emerging growth, smaller reporting company whose common stock trades on Nasdaq under AMST. Recent Form 8-K disclosures cover material agreements, Regulation FD shareholder updates, Nasdaq continued-listing matters, changes in the company’s independent registered public accounting firm, and updates on the NurseMagic AI-native documentation and workflow platform for non-acute care.
The company’s registration and financing filings describe securities offerings, shelf registration use, common stock, pre-funded warrants, private-placement warrants, resale registration matters, and related stockholder-approval mechanics. These filings also provide formal disclosure on capital structure, governance, risk factors, and public-company reporting obligations.
LOSH J MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
Amesite Inc. director J. Michael Losh, through the J. Michael Losh Irrevocable Qualified Annuity Trust #7, received a grant of 10,902 restricted stock units as deferred stock units in lieu of cash director fees. Each unit represents one share of AMST common stock or its cash equivalent, deliverable after board service ends or upon an earlier change in control. Following this award, the trust holds 101,265 units in total.
Brewer Barbie reported acquisition or exercise transactions in this Form 4 filing.
Amesite Inc. director Barbie Brewer received a grant of 10,432 restricted stock units as board compensation. Each RSU represents a right to receive one share of common stock or its cash equivalent. The units were issued in lieu of cash fees and will be settled when board service ends or upon a change in control.
Amesite Inc. is calling a virtual annual stockholder meeting on July 13, 2026 to vote on key governance and financing items. Stockholders of record as of May 22, 2026, when 5,852,985 common shares were outstanding, may participate and vote online.
Proposals include re-electing two directors, ratifying Novogradac & Company LLP as the new independent auditor, amending the 2018 Equity Incentive Plan to add 1,000,000 shares for future awards, and approving the issuance of up to 2,787,464 shares upon exercise of private placement warrants. The proxy explains quorum, broker non-votes, director independence, board committees and director compensation, highlighting Amesite’s reliance on stock-based incentives to attract and retain executives, employees and non-employee directors.
Amesite Inc. filed Amendment No. 1 to its Form S-1 registration statement as an exhibit-only update. The change is limited to correcting a technical error in the auditor consent filed as Exhibit 23.1, leaving the substantive terms of the registration statement unchanged.
The company discloses estimated offering-related expenses of $60,674.56, including a $674.56 SEC registration fee, $30,000.00 of accounting fees, $25,000.00 of legal fees, and $5,000.00 of miscellaneous costs. Amesite also lists prior unregistered issuances, including employee stock options and shares to consultants under its equity incentive plan.
Amesite Inc. disclosed that its NurseMagic™ AI documentation platform has secured a new enterprise customer with an approximately 2,700-patient census, the company’s largest deployment to date. The customer will roll out NurseMagic™ across its workforce to integrate EMR and EVV workflows and reduce administrative tasks that can consume up to 16 hours per caregiver per week.
The company describes this as a step-change in scale that validates NurseMagic™ as core clinical infrastructure for the non-acute/post-acute market. Management also highlights approximately an 18% reduction in operating spend over the last six quarters, a growing base of paying customers, and digital demand metrics including about 4,200 web visits per day and strong inbound interest from providers.
Amesite Inc. reported higher revenue but continued losses and liquidity pressures for the quarter ended March 31, 2026. Net revenue reached $83,332 for the quarter and $285,678 for the nine months, up sharply from the prior-year periods, reflecting a pivot toward AI-driven healthcare solutions such as its NurseMagic™ app.
The company still posted a net loss of $678,061 for the quarter and $2,052,875 for the nine months, with cash, cash equivalents and restricted cash of only $740,711 as of March 31, 2026. Management concludes that recurring losses and limited cash raise substantial doubt about Amesite’s ability to continue as a going concern.
On April 28, 2026, Amesite completed a registered direct offering and related private placements, issuing common stock and warrants for aggregate gross proceeds of about $2.6 million (approximately $2.2 million net), including insider participation. This capital raise is expected to fund working capital and also helped restore compliance with Nasdaq’s minimum stockholders’ equity requirement, though maintaining that compliance will depend on future results.
Amesite Inc. director and chief executive officer Ann Marie Sastry reported buying additional equity on April 28, 2026. She purchased 174,216 shares of common stock at $1.435 per share in a private placement pursuant to a securities purchase agreement and now holds 1,049,647 common shares directly. On the same date, she also acquired Series A-1 and Series A-2 warrants, each covering 174,216 underlying common shares at a $1.435 exercise price, with expirations on April 28, 2031 and October 28, 2027, respectively.
Amesite Inc. director George Parmer reported a net purchase of Amesite securities. He bought 243,902 shares of Common Stock at $1.435 per share in a private placement pursuant to a securities purchase agreement. Following this, he directly holds 566,962 Common shares.
Parmer also acquired 243,902 Series A-2 Warrants and 243,902 Series A-1 Warrants, each giving the right to buy Common Stock at an exercise price of $1.435 per share. The Series A-2 Warrants expire on October 28, 2027, and the Series A-1 Warrants expire on April 28, 2031. These transactions were made in connection with the same private placement offering described in an Amesite 424(b)(5) prospectus supplement.
Amesite Inc. notified the SEC that its Form 10-Q for the period ended March 31, 2026 could not be filed on time due to time constraints in compiling, disseminating and reviewing required information. The company states it will file the Form 10-Q no later than 5 calendar days after the original due date.